Tržní kapitalizace společnosti Beam Therapeutics
Jaká je hodnota metriky Tržní kapitalizace společnosti Beam Therapeutics?
Hodnota metriky Tržní kapitalizace společnosti Beam Therapeutics Inc. je $3.16B
Jaká je definice metriky Tržní kapitalizace?
Tržní kapitalizace (Market cap) je tržní hodnotou vydaných akcií obchodované společnosti a rovná se ceně akcií v daném čase vynásobené počtem kusů vydaných akcií .
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Tržní kapitalizace společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Beam Therapeutics
Čemu se věnuje společnost Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Firmy s metrikou tržní kapitalizace podobnou společnosti Beam Therapeutics
- Hodnota metriky Tržní kapitalizace společnosti Quaker Houghton je $3.15B
- Hodnota metriky Tržní kapitalizace společnosti Sichuan Teway Food Co.,Ltd je $3.15B
- Hodnota metriky Tržní kapitalizace společnosti Transocean Ltd je $3.15B
- Hodnota metriky Tržní kapitalizace společnosti Imerys S.A je $3.16B
- Hodnota metriky Tržní kapitalizace společnosti Inmode Ltd je $3.16B
- Hodnota metriky Tržní kapitalizace společnosti Vishay Intertechnology je $3.16B
- Hodnota metriky Tržní kapitalizace společnosti Beam Therapeutics je $3.16B
- Hodnota metriky Tržní kapitalizace společnosti Drax plc je $3.17B
- Hodnota metriky Tržní kapitalizace společnosti The Bank of East Asia je $3.17B
- Hodnota metriky Tržní kapitalizace společnosti Njtc je $3.17B
- Hodnota metriky Tržní kapitalizace společnosti California Resources je $3.17B
- Hodnota metriky Tržní kapitalizace společnosti Tiscali Spa je $3.17B
- Hodnota metriky Tržní kapitalizace společnosti Sun Art Retail je $3.17B